Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0KGHP)

• Drug Name: [3H](-)devapamil Drug Info
• Synonyms: (-)-Desmethoxyverapamil; (-)-Devapamil; 4-Desmethoxyverapamil; UNII-99EAI85506; 99EAI85506; 93468-87-2; (2S)-2-(3,4-dimethoxyphenyl)-5-[2-(3-methoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; AC1L32ZZ; AC1Q4Q2Z; 4-DMV; (-)-H3-Desmethoxyverapamil; GTPL2515; GTPL2517; SCHEMBL10453636; 4-desmethoxyverapamil (4-DMV); ZINC2016058; PDSP2_001070; PDSP1_001086; benzeneacetonitrile, 3,4-dimethoxy-; A-(3-((2-(3-methoxyphenyl)ethyl)methylamino)propyl)-; A-(1-methylethyl)-,(s)-; D888; D 888; D-888; (-)-D888; Desmethoxyverapamil

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 107928
  CAS Number: CAS 93468-87-2
  TTD Drug ID: DM0KGHP

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[5]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[6]
[3H](+)-cis-diltiazem	DMP6XL9	Discovery agent	N.A.	Investigative	[7]
FPL64176	DMB8U4F	Discovery agent	N.A.	Investigative	[5]
SZ(+)-(S)-202-791	DM8L6ZF	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAUWOLFIA SERPENTINA ROOT	DMWTVAN	Discovery agent	N.A.	Approved	[8]
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[9]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[10]
NIGULDIPINE	DMSPWMF	N. A.	N. A.	Terminated	[8]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[11]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[12]
R-56865	DMYTI3J	Angina pectoris	BA40	Terminated	[13]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[14]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[15]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Voltage-gated L-type calcium channel (L-CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[16]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[17]
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[18]
Otilonium bromide	DM05968	Gastric motility disorder	DA21	Approved	[19]
Levamlodipine	DM92S6N	Hypertension	BA00-BA04	Phase 4	[20]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[21]
Pinaverium bromide	DM7OSHC	Irritable bowel syndrome	DD91.0	Phase 3	[19]
MEM-1003	DMYZU6G	Bipolar disorder	6A60	Phase 2a	[22]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[4]
BAY-Y-5959	DMLO18H	Cardiovascular disease	BA00-BE2Z	Phase 2	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.1 (CACNA1S)	TT94HRF	CAC1S_HUMAN	Inhibitor (gating inhibitor)	[2]
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)	TTZIFHC	CAC1C_HUMAN	Inhibitor (gating inhibitor)	[3]
Voltage-gated L-type calcium channel (L-CaC)	TTXHYV6	NOUNIPROTAC	Blocker	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2515).
• [2] (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371-7.
• [3] Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41.
• [4] Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528).
• [6] Biochemical characterization of plasma membrane isolated from human skeletal muscle. FEBS Lett. 1985 Sep 2;188(2):222-6.
• [7] High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels. J Pharmacol Exp Ther. 1997 Apr;281(1):173-9.
• [8] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [9] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [10] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [12] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [13] Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
• [14] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [18] Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
• [19] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [20] Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
• [21] N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
• [22] Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
• [23] Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.